Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Receivables: 2012-2024

Historic Change in Receivables for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $6.2 million.

  • Ocular Therapeutix's Change in Receivables rose 11766.67% to $356,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $533,000, marking a year-over-year decrease of 91.98%. This contributed to the annual value of $6.2 million for FY2024, which is 27.92% up from last year.
  • Ocular Therapeutix's Change in Receivables amounted to $6.2 million in FY2024, which was up 27.92% from $4.9 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Change in Receivables ranged from a high of $9.7 million in FY2020 and a low of $190,000 during FY2022.
  • In the last 3 years, Ocular Therapeutix's Change in Receivables had a median value of $4.9 million in 2023 and averaged $3.8 million.
  • In the last 5 years, Ocular Therapeutix's Change in Receivables tumbled by 97.86% in 2022 and then soared by 2,454.74% in 2023.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Change in Receivables stood at $9.7 million in 2020, then declined by 8.46% to $8.9 million in 2021, then slumped by 97.86% to $190,000 in 2022, then skyrocketed by 2,454.74% to $4.9 million in 2023, then grew by 27.92% to $6.2 million in 2024.